Risk factor
Very high price volatility
Profitability factor
Strong growth
About
Artrya Limited operates as a medical technology company that uses artificial intelligence (AI) to identify patients at risk of coronary artery disease. It offers Salix, a cloud-based software that uses its AI to automate the detection of coronary artery disease from coronary computed tomography angiography. The company was incorporated in 2018 and is based in...
Company Valuation
Based on key historical and expected multiples, the stock is greatly overvalued relative to its peers. Specifically, the stock is overvalued on EV/EBITDA.
Target Price
The average target price of AYA.AX is 3.1 and suggests 13% downside potential. Usually, this means a SELL recommendation among investment firms, or a recommendation to de
Buy
Sell